Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody

[1]  J. Antoine,et al.  Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy , 2014, Journal of the Neurological Sciences.

[2]  Jun Kimura,et al.  Principles of Nerve Conduction Studies , 2013 .

[3]  A. Steck,et al.  Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathy , 2013, Neurology.

[4]  D. Cornblath,et al.  Rapid worsening of IgM anti‐MAG demyelinating polyneuropathy during rituximab treatment , 2013, Journal of the peripheral nervous system : JPNS.

[5]  G. Sobue,et al.  Differential, size-dependent sensory neuron involvement in the painful and ataxic forms of primary Sjögren's syndrome-associated neuropathy , 2012, Journal of the Neurological Sciences.

[6]  J. Lünemann,et al.  Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. , 2012, The Journal of clinical investigation.

[7]  M. A. Sheddi.  A clinicopathological study , 2012 .

[8]  G. Sobue,et al.  Morphological Progression of Myelin Abnormalities in IgM-Monoclonal Gammopathy of Undetermined Significance Anti-Myelin-Associated Glycoprotein Neuropathy , 2010, Journal of neuropathology and experimental neurology.

[9]  G. Sobue,et al.  IgM MGUS anti‐MAG neuropathy with predominant muscle weakness and extensive muscle atrophy , 2010, Muscle & nerve.

[10]  M. Dalakas.  Pathogenesis and Treatment of Anti-MAG Neuropathy , 2010, Current treatment options in neurology.

[11]  M. Dalakas,et al.  Practical considerations on the use of rituximab in autoimmune neurological disorders , 2010, Therapeutic advances in neurological disorders.

[12]  G. Sobue,et al.  Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP , 2009, Neurology.

[13]  L. H. van den Berg,et al.  Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy , 2009, Neurology.

[14]  H. Franssen,et al.  Rituximab for polyneuropathy with IgM monoclonal gammopathy , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  J. Dambrosia,et al.  Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy , 2009, Annals of neurology.

[16]  L. Padua,et al.  LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY , 2008, Neurology.

[17]  M. Dalakas.  Invited Article: Inhibition of B cell functions , 2008, Neurology.

[18]  G. Sobue,et al.  Nonmyelinating Schwann Cell Involvement With Well-Preserved Unmyelinated Axons in Charcot-Marie-Tooth Disease Type 1A , 2007, Journal of neuropathology and experimental neurology.

[19]  L. H. van den Berg,et al.  Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy , 2007, Neurology.

[20]  M. Sormani,et al.  Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin M , 2007, Journal of the peripheral nervous system : JPNS.

[21]  G. Lauria,et al.  Worsening after rituximab treatment in anti‐mag neuropathy , 2005, Muscle & nerve.

[22]  G. Sobue,et al.  Age associated axonal features in HNPP with 17p11.2 deletion in Japan , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  G. Sobue,et al.  Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP , 2005, Neurology.

[24]  P. Dyck,et al.  Chapter 32 – Pathologic Alterations of Nerves , 2005 .

[25]  A. Steck,et al.  Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases , 2004, Journal of Neurology.

[26]  G. Sobue,et al.  Alcoholic neuropathy is clinicopathologically distinct from thiamine‐deficiency neuropathy , 2003, Annals of neurology.

[27]  G. Deuschl,et al.  Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies , 2003, Muscle & nerve.

[28]  Timothy A. Miller,et al.  Treatment of IgM antibody associated polyneuropathies using rituximab , 2003, Journal of neurology, neurosurgery, and psychiatry.

[29]  G. Sobue,et al.  Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. , 2003, Brain : a journal of neurology.

[30]  I. Kanazawa,et al.  Variability in immunohistochemistries of IgM M-proteins binding to sulfated glucuronyl paragloboside , 2001, Journal of Neuroimmunology.

[31]  A. Steck,et al.  Anti‐MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening , 1999, Muscle & nerve.

[32]  A. Pestronk,et al.  IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab , 1999, Neurology.

[33]  M. Dalakas,et al.  Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia , 1999, Journal of Neuroimmunology.

[34]  J. Gabriel,et al.  Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy , 1998, Acta Neuropathologica.

[35]  G. Rosoklija,et al.  Anti‐MAG and anti‐SGPG antibodies in neuropathy , 1996, Muscle & nerve.

[36]  N. Latov.  Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies , 1995, Annals of neurology.

[37]  G. Moretto,et al.  Experimental Induction of Myelin Changes by Anti‐MAG Antibodies and Terminal Complement Complex , 1995, Journal of neuropathology and experimental neurology.

[38]  M. Schachner,et al.  The L2/HNK-1 carbohydrate is preferentially expressed by previously motor axon-associated Schwann cells in reinnervated peripheral nerves , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[39]  I. S. Smith.  The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study. , 1994, Brain : a journal of neurology.

[40]  S. Barbieri,et al.  Frequency and clinical correlates of anti–neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy , 1994, Annals of neurology.

[41]  A. Tatum.  Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti‐myelin‐associated glycoprotein , 1993, Annals of neurology.

[42]  M. B. Katirji,et al.  Neuroimmune Networks , 1990, Neurology.

[43]  G. Sobue,et al.  X-linked recessive bulbospinal neuronopathy. A clinicopathological study. , 1989, Brain : a journal of neurology.

[44]  J. Kimura.  Assessment of individual nerves. , 1989 .

[45]  S. Barbieri,et al.  Treatment of patients with neuropathy and anti‐MAG IgM M‐proteins , 1988, Annals of neurology.

[46]  H. Schouten,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[47]  A. Hays,et al.  Peripheral neuropathy and anti-MAG antibodies. , 1988, Critical reviews in neurobiology.

[48]  A. Steck,et al.  Peripheral neuropathy associated with monoclonal IgM autoantibody , 1987, Annals of neurology.

[49]  A. Hays,et al.  Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti‐MAG IgM M‐protein , 1987, Neurology.

[50]  H. Weiner,et al.  Monoclonal gammopathy and neuropathy , 1986, Neurology.

[51]  Jun Kimura,et al.  Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice , 1983 .

[52]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.